close print view
Cancer Genomics EpidemiologyBackground
The Michigan Department of Community Health, in collaboration with the Centers for Disease Control and Prevention, has created a multi-faceted, comprehensive cancer genomics program that encompasses public health surveillance, health education of providers, and policy interventions with health insurance plans.
The ultimate impact of these activities would be a reduction in early cancer deaths (before age 50) in Michigan residents as a result of appropriate translation of cancer genetic tests into clinical and public health practice, statewide surveillance and implementation of systems of care for inherited breast and ovarian cancer, and the use of best practice recommendation for family history, cancer genetic counseling and testing (BRCA1/2).
Cancer is the second leading cause of death in Michigan and the United States. Cancers diagnosed before age 50 represent a meaningful portion of the state's cancer burden and cancers with early onset are more likely to represent hereditary forms of cancer.
BRCA1 and 2 mutations are dominant germline mutations that are associated with breast cancer diagnosed at an early age and ovarian cancer at any age. BRCA1/2 is responsible for 5-10% of all breast cancers and about 20% of breast cancer diagnosed in women under age 45. It is also responsible for 6% of ovarian cancers. Mutations in BRCA 1 and 2 confer an estimated 35-84% chance of a woman developing breast cancer by age 70 (compared to 10-12% in the general population) and a 10-50% chance of developing ovarian cancer.
Lynch syndrome is the most common form of a genetically determined colon cancer predisposition. It accounts for 3% of colorectal cancer diagnoses. The risk of developing colorectal cancer by age 70 in mutation carriers is estimated to be between 24 and 75% (compared to 4-5% in the general population), while the risk of endometrial cancer is between 27-70% (compared to 2-3% in the general population).
Cancer Genomics Epidemiology Staff
What We Do
Our goal is to develop and implement a model for surveillance of inherited cancer and use of relevant genetic tests. Through the use of multiple data sets, including the Michigan Cancer Surveillance Program's registry data and clinical genetics data, we are monitoring the prevalence of disease, the use of clinical genetic services and the quality of care that is provided.
More publications and presentations related to cancer genomics in Michigan can be found at the Michigan Public Health Genomics Program website.
Links to other sites related to cancer genomics epidemiology:
Copyright © 2001-2014 State of Michigan